View Item 

Show simple item record

Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure
dc.contributor.authorDewan, Pooja
dc.contributor.authorJackson, Alice
dc.contributor.authorLam, Carolyn S.P.
dc.contributor.authorPfeffer, Marc A.
dc.contributor.authorZannad, Faiez
dc.contributor.authorPitt, Bertram
dc.contributor.authorSolomon, Scott D.
dc.contributor.authorMcMurray, John J.V.
dc.date.accessioned2020-06-03T15:24:23Z
dc.date.availableWITHHELD_12_MONTHS
dc.date.available2020-06-03T15:24:23Z
dc.date.issued2020-05
dc.identifier.citationDewan, Pooja; Jackson, Alice; Lam, Carolyn S.P.; Pfeffer, Marc A.; Zannad, Faiez; Pitt, Bertram; Solomon, Scott D.; McMurray, John J.V. (2020). "Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure." European Journal of Heart Failure 22(5): 898-901.
dc.identifier.issn1388-9842
dc.identifier.issn1879-0844
dc.identifier.urihttps://hdl.handle.net/2027.42/155546
dc.publisherJohn Wiley & Sons, Ltd.
dc.titleInteractions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelCardiovascular Medicine
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/155546/1/ejhf1776.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/155546/2/ejhf1776_am.pdf
dc.identifier.doi10.1002/ejhf.1776
dc.identifier.sourceEuropean Journal of Heart Failure
dc.identifier.citedreferenceSolomon SD, McMurray JJ, Anand IS, Ge J, Lam CS, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin‐Colet J, Cleland J, Düngen H‐D, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP; PARAGON‐HF Investigators and Committees. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019; 381: 1609 – 1620.
dc.identifier.citedreferenceSolomon SD, Vaduganathan M, Claggett BL, Packer M, Zile M, Swedberg K, Rouleau J, Pfeffer MA, Desai A, Lund LH, Koeber L, Anand I, Sweitzer NK, Linssen G, Merkely B, Arango JL, Vinereanu D, Chen C‐H, Senni M, Sibulo A, Boytsov S, Shi V, Rizkala A, Lefkowitz M, McMurray JJ. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation 2020; 141: 352 – 361.
dc.identifier.citedreferenceMcMurray JJ, Jackson AM, Lam CS, Redfield MM, Anand IS, Ge J, Lefkowitz MP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Rizkala AR, Sabarwal SV, Shah AM, Shah SJ, Shi VC, Veldhuisen DJ van, Zannad F, Zile MR, Cikes M, Goncalvesova E, Katova T, Kosztin A, Lelonek M, Sweitzer NK, Vardeny O, Claggett B, Jhund PS, Solomon SD. Effects of sacubitril‐valsartan, versus valsartan, in women compared to men with heart failure and preserved ejection fraction: insights from PARAGON‐HF. Circulation 2020; 141: 338 – 351.
dc.identifier.citedreferenceDewan P, Rørth R, Jhund PS, Shen L, Raparelli V, Petrie MC, Abraham WT, Desai AS, Dickstein K, Køber L, Mogensen UM, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, McMurray JJ. Differential impact of heart failure with reduced ejection fraction on men and women. J Am Coll Cardiol 2019; 73: 29 – 40.
dc.identifier.citedreferenceDewan P, Rørth R, Raparelli V, Campbell RT, Shen L, Jhund PS, Petrie MC, Anand IS, Carson PE, Desai AS, Granger CB, Køber L, Komajda M, Mckelvie RS, Meara EO, Pfeffer MA, Pitt B, Solomon SD, Swedberg K, Zile MR, McMurray JJ: Sex‐related differences in heart failure with preserved ejection fraction. Circ Heart Fail 2019; 12: e006539.
dc.identifier.citedreferenceEchocardiographic Normal Ranges Meta‐Analysis of the Left Heart Collaboration. Ethnic‐specific normative reference values for echocardiographic LA and LV size, LV mass, and systolic function: the EchoNoRMAL study. JACC Cardiovasc Imaging 2015; 8: 656 – 665.
dc.identifier.citedreferenceGori M, Lam CS, Gupta DK, Santos AB, Cheng S, Shah AM, Claggett B, Zile MR, Kraigher‐Krainer E, Pieske B, Voors AA, Packer M, Bransford T, Lefkowitz M, McMurray JJ, Solomon SD; PARAMOUNT Investigators. Sex‐specific cardiovascular structure and function in heart failure with preserved ejection fraction. Eur J Heart Fail 2014; 16: 535 – 542.
dc.identifier.citedreferencePonikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González‐Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891 – 975.
dc.identifier.citedreferencePfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Östergren J, Yusuf S, Pocock S; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM‐Overall programme. Lancet 2003; 362: 759 – 766.
dc.identifier.citedreferencePitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709 – 717.
dc.identifier.citedreferenceZannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS‐HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11 – 21.
dc.identifier.citedreferencePitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383 – 1392.
dc.identifier.citedreferenceMcMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM‐HF Investigators and Committees. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993 – 1004.
dc.identifier.citedreferenceSolomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O’Meara E, Shah SJ, McKinlay S, Fleg JL, Sopko G, Pitt B, Pfeffer MA; TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 2016; 37: 455 – 462.
dc.identifier.citedreferenceLund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, Swedberg K, Yusuf S, Granger CB, Pfeffer MA, McMurray JJ, Solomon SD. Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 2018; 20: 1230 – 1239.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ejhf1776.pdf
Size:
289.5KB
Format:
PDF
View/Open
Name:
ejhf1776_am.pdf
Size:
586.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.